Results 31 to 40 of about 5,080 (193)
Advanced Science, EarlyView.Engineered exosomal siRNA delivery platform enables systemic, neuron‐targeted RNA transport across the blood–brain barrier. Surface functionalization with rabies virus glycoprotein‐derived peptide facilitates receptor‐mediated transcytosis, achieving efficient cytosolic delivery and robust gene silencing. Targeting RIPK3 suppresses necroptosis, reduces
Chi Zhang +9 more
wiley +1 more source
CPT: Pharmacometrics & Systems PharmacologyLecanemab (Leqembi®) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease upon ...
Oneeb Majid +10 more
doaj +1 more source
Advanced Science, EarlyView.Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...
Ziwei Ren +11 more
wiley +1 more source
Advanced Science, EarlyView.A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung +15 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review
Neurology and Clinical Neuroscience, EarlyView.ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques +4 more
wiley +1 more source
CPT: Pharmacometrics & Systems PharmacologyLecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to protofibrils of amyloid‐beta (Aβ) protein. In clinical studies, lecanemab has been shown to reduce amyloid markers in early symptomatic Alzheimer's disease and slow decline ...
Pratik Bhagunde +7 more
doaj +1 more source
Phytotherapy Research, EarlyView.Research landscape and mechanistic insights into natural medicines for Alzheimer's disease. ABSTRACT Natural medicines have been widely investigated for Alzheimer's disease (AD), but the development of this field and the relationship between bibliometric themes and experimental evidence remain insufficiently characterized.
Maoning Wang +8 more
wiley +1 more source
Lecanemab and APOE Genotyping in Clinical Practice-Navigating Uncharted Terrain [PDF]
, 2023 Publication of results from the phase 3 Lecanemab for People with Early Alzheimer's Disease (Clarity AD) trial, with demonstration that the drug provided a small clinical benefit and may have slowed disease progression, has brought hope to millions of ...
Thambisetty, Madhav, Howard, Robert
core +1 more source
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease MonitoringIntroduction Lecanemab, an anti‐amyloid‐beta antibody, is approved in over 40 countries. Patient demographic data exist for the US but are limited elsewhere. This study examined early real‐world lecanemab use in Japan.
Kengo Kawaguchi +4 more
doaj +1 more source